Compare TransMedics Group Inc (TMDX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Western Alliance Bancorporation — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Western Alliance Bancorporation trades at $79.37 (market cap $8.72B). The key difference: Western Alliance Bancorporation is far larger — about 2.8× TransMedics Group Inc's market cap, and Western Alliance Bancorporation pays a 2.1% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WAL | |
|---|---|---|
Market Cap | $3.06B | $8.72B |
Sector | Technology | Financials |
52-Week High | $150.42 | $96.08 |
52-Week Low | $61.99 | $66.70 |
Enterprise Value | $3.46B | — |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Western Alliance Bancorporation (WAL) trades at $79.94, down 1.25% on the day, with a bearish technical signal despite strong fundamentals. The bank reported Q2 2026 earnings that met revenue expectations but slightly missed EPS estimates, while maintaining robust profitability with a 25.43% net income margin and 13.43% ROE. Recent developments include the launch of WA VenueX™ digital asset platform and recognition as Arizona's #1 bank by Forbes.
WAL presents a compelling value opportunity with a P/E of 9.02 and strong analyst support (79% buy ratings, $93.86 consensus target), though negative operating cash flow and bearish technical indicators warrant caution. The stock offers 17% upside to consensus target but faces headwinds from declining cash flow and mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
